All In Biotech

Drug Trial Radar · NCT04375033

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

CSP #2014 - Comparative Effectiveness of Two Formulations of Buprenorphine for Treating Opioid Use Disorder in Veterans (VA-BRAVE)

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 952 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

952

Planned (sponsor's estimate)

Start

Nov 3, 2020

Primary completion

Sep 30, 2028

Study completion May 31, 2029

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
May 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous formulation of buprenorphine at a target dose of 300 milligrams (mg) is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 4-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.

Conditions

  • Opioid Use Disorder

Interventions

  • Sublingual buprenorphine with naloxoneDrug

    The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit through Week 48.

  • Injectable subcutaneous buprenorphineDrug

    Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously at each 28-day visit through Week 48.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Retention in Treatment ChangeTime frame: Approximately every 4 weeks until the first period of missed prescription medication coverage lasting at least 4 weeks through week 52
  2. Opioid AbstinenceTime frame: Approximately every 2 weeks through 52 weeks (active phase) and via EMR review for up to 10 years (passive phase)

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Tuscaloosa VA Medical Center, Tuscaloosa, AL

    Tuscaloosa, Alabama · Terminated

  • Phoenix VA Health Care System, Phoenix, AZ

    Phoenix, Arizona · Recruiting

  • VA Long Beach Healthcare System, Long Beach, CA

    Long Beach, California · Recruiting

  • VA Palo Alto Health Care System, Palo Alto, CA

    Palo Alto, California · Recruiting

  • San Francisco VA Medical Center, San Francisco, CA

    San Francisco, California · Recruiting

  • CERC (VISN1, West Haven, CT)

    West Haven, Connecticut · Recruiting

  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT

    West Haven, Connecticut · Active not recruiting

  • Wilmington VA Medical Center, Wilmington, DE

    Wilmington, Delaware · Recruiting

  • Bay Pines VA Healthcare System, Pay Pines, FL

    Bay Pines, Florida · Recruiting

  • North Florida/South Georgia Veterans Health System, Gainesville, FL

    Gainesville, Florida · Recruiting

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

    Boston, Massachusetts · Terminated

  • Minneapolis VA Health Care System, Minneapolis, MN

    Minneapolis, Minnesota · Terminated

  • Louis Stokes VA Medical Center, Cleveland, OH

    Cleveland, Ohio · Terminated

  • Dayton VA Medical Center, Dayton, OH

    Dayton, Ohio · Recruiting

  • Philadelphia MultiService Center, Philadelphia, PA

    Philadelphia, Pennsylvania · Recruiting

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

    Pittsburgh, Pennsylvania · Terminated

  • Providence VA Medical Center, Providence, RI

    Providence, Rhode Island · Terminated

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX

    Dallas, Texas · Recruiting

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah · Recruiting

  • White River Junction VA Medical Center, White River Junction, VT

    White River Junction, Vermont · Terminated

  • Hampton VA Medical Center, Hampton, VA

    Hampton, Virginia · Recruiting

  • Salem VA Medical Center, Salem, VA

    Salem, Virginia · Recruiting

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    Seattle, Washington · Recruiting

  • Huntington VA Medical Center, Huntington, WV

    Huntington, West Virginia · Recruiting

  • Clement J. Zablocki VA Medical Center, Milwaukee, WI

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.